BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:2022 hosts the race between IVERIC Bio and Apellis for regulat
 ory approval of the very first marketable dry AMD treatment. In addition 
 to clinical advances\, the field will see plenty of technology advances f
 or more patient-compliant therapeutics\, with the favourable one-dose gen
 e therapy approach addition to pipelines\, and optimized biomarker techno
 logy.\n\nJoin our 30+ expert speakers as we tackle the most critical road
 blocks preventing your drugs getting the patients who need them. With com
 panies such as Janssen\, Apellis\, Novartis\, IVERIC\, Genentech\, AbbVie
  and more\, we'll delve into the role of genetics\, subretinal drusenoid 
 deposits\, lipid peroxidation and soft drusen in the progression dry AMD\
 ; realize the future of next generation biomarkers such as OCT technologi
 es for novel structural endpoints and pharmacodynamic biomarkers such as 
 DKK3 to\; discuss better utilization of animal models and novel patient d
 erived iPSC models to overcome translational challenges such as poor reca
 pitulation of the human eye and much more content.\n
DTEND:20221202T120000
DTSTAMP:20260512T214259Z
DTSTART:20221130T075000
LOCATION:Revere Hotel Boston Common\, 200\, 200 Stuart Street\, Boston\, M
 assachusetts\, 02116\,
SEQUENCE:0
SUMMARY:2022 hosts the race between IVERIC Bio and Apellis for regulatory 
 approval of the very first marketable dry AMD treatment. In addition to c
 linical...
UID:a00e455b-eb71-49b7-8f2f-94e7e219ac36
END:VEVENT
END:VCALENDAR